ZM 014
Alternative Names: ZM-014Latest Information Update: 03 Aug 2022
At a glance
- Originator Zumutor Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Lymphoma
Most Recent Events
- 21 Jul 2022 Early research in Lymphoma in USA (Parenteral) (Zumutor Biologics pipeline, July 2022)